Bodtger Uffe, Linneberg Allan
Allergy Clinic, Copenhagen University Hospital, Copenhagen, Denmark.
J Allergy Clin Immunol. 2004 Dec;114(6):1384-8. doi: 10.1016/j.jaci.2004.08.039.
Allergic rhinitis (AR) and sensitization are considered chronic conditions. However, few studies have reported remission rates in adults.
We sought to estimate the incidence of remission of AR during an 8-year period.
Participants in a population-based study of 15- to 69-year-old patients in 1990 were invited to a follow-up in 1998. Questionnaires on respiratory symptoms and serum for specific IgE (s-IgE) analyses were collected at both visits in 734 subjects (69% of those invited). Pollen AR was defined as rhinitis symptoms on pollen exposure within the last 12 months and s-IgE levels of class 2 or greater against pollen (birch, grass, or mugwort). This was similar for AR to animals (cat or dog) or house dust mites (HDMs). Remission of AR was defined as AR at baseline but no rhinitis symptoms at follow-up and sensitization (s-IgE level class > or =2 at baseline and class <2 at follow-up).
Remission of AR occurred in 12% (pollen AR), 19% (animal AR), and 38% (HDM AR; overall, 17%) and was predicted by low s-IgE levels. Age, sex, asthma, atopic predisposition, age at AR onset, and AR duration had no predictive value. A decrease in s-IgE level was observed in only 22% of remitting subjects yet was seen significantly more often than in nonremitting subjects (7.4%). Remission of sensitization occurred in 6% (HDM) to 11% (pollen-furry animal) and was predicted on the basis of low s-IgE levels (class 2) at baseline.
Remission of AR symptoms was relatively infrequent, and remission of both symptoms and IgE sensitization was rare. The results underline the chronic nature of AR in adulthood.
变应性鼻炎（AR）和致敏被视为慢性疾病。然而，很少有研究报道成人的缓解率。
我们试图估算8年间AR的缓解发生率。
邀请1990年一项针对15至69岁患者的基于人群的研究中的参与者于1998年进行随访。在两次访视时收集了734名受试者（受邀者的69%）的呼吸道症状问卷和用于特异性IgE（s-IgE）分析的血清。花粉性AR定义为在过去12个月内接触花粉时出现鼻炎症状且针对花粉（桦树、草或艾蒿）的s-IgE水平为2级或更高。动物（猫或狗）或屋尘螨（HDM）所致AR的定义与此类似。AR的缓解定义为基线时有AR但随访时无鼻炎症状且致敏（基线时s-IgE水平为≥2级且随访时<2级）。
AR缓解发生于12%（花粉性AR）、19%（动物所致AR）和38%（HDM所致AR；总体为17%），且由低s-IgE水平预测。年龄、性别、哮喘、特应性易感性、AR起病年龄和AR病程无预测价值。仅22%的缓解受试者出现s-IgE水平下降，但明显比未缓解受试者更常见（7.4%）。致敏缓解发生于6%（HDM）至11%（花粉-多毛动物），并根据基线时低s-IgE水平（2级）预测。
AR症状缓解相对少见，症状和IgE致敏同时缓解则罕见。结果强调了成年期AR的慢性本质。
